MRI-Based Multifunctional Nanoliposomes for Enhanced HCC Therapy and Diagnosis

Area of Science:

• Biomedical Engineering
• Nanotechnology
• Oncology

Background:

• Hepatocellular carcinoma (HCC) presents high morbidity and mortality rates, with limited efficacy of single therapies due to tumor heterogeneity and drug resistance.
• Lack of real-time tumor monitoring during treatment contributes to poor therapeutic outcomes.
• Nanodelivery platforms integrating therapy and diagnosis are crucial for advancing HCC treatment.

Purpose of the Study:

• To develop a multifunctional nanodelivery vector for combined hepatocellular carcinoma (HCC) therapy and diagnosis.
• To utilize the nanodelivery system for magnetic resonance imaging (MRI)-guided treatment and monitoring of HCC.
• To evaluate the synergistic therapeutic effects of doxorubicin (DOX) and GPC3 gene silencing in HCC treatment.

Main Methods:

• Development of LPSD-DOX/siRNA, a nanodelivery vector incorporating oleic acid-modified superparamagnetic iron oxide nanoparticles (OA-SPION), doxorubicin (DOX), and DOTAP-modified siRNA targeting Glypican-3 (GPC3).
• Assessment of drug loading, gene transfection efficiency, and in vitro toxicity.
• Pharmacokinetic and biodistribution studies to evaluate in vivo drug circulation and tumor accumulation.
• Utilized MRI for tumor imaging and monitoring.
• Evaluated antitumor efficacy in HepG2 cell-transplanted tumor models.

Main Results:

• LPSD-DOX/siRNA demonstrated high drug loading, efficient gene transfection, and low toxicity.
• The nanodelivery system significantly prolonged DOX circulation time and enhanced tumor-specific drug accumulation.
• MRI confirmed LPSD-DOX/siRNA's capability as a T2 contrast agent for improved tumor visualization and monitoring.
• Combined therapy significantly inhibited GPC3 protein expression, increased tumor apoptosis, and suppressed tumor growth.

Conclusions:

• LPSD-DOX/siRNA represents a promising multifunctional nanodelivery strategy for synergistic HCC therapy and diagnostic monitoring.
• This approach enhances antitumor efficacy by combining chemotherapy with targeted gene silencing and real-time imaging.
• The developed nanodelivery system holds significant potential for improving HCC treatment outcomes.